At the tail end of this operation are transfer RNAs, which, as the name suggests, carry and ultimately hand off the correct building blocks — known as amino acids — to the ribosome. But despite their crucial role, these molecules haven’t attracted as much attention as other types of RNA. An article published not too long ago in the journal Cell Research claimed tRNA is “generally not on the mind of most research scientists, unless they meet it through chance encounter.” Now named Alltrna, the company officially launched on November 09th with an initial commitment of $50 million from Flagship. The firm’s origination partner, Lovisa Afzelius, is serving as Alltrna’s founding CEO, while Anastassiadis, in addition to being a co-founder, is taking on the role of chief innovation officer.
For further information, see Biopharma Dive (https://www.biopharmadive.com/news/flagship-alltrna-transfer-rna-biotech-launch/609706/)